# US 12,005,090 B2 · Probiotic composition including lactic acid bacterial strains and use of at least one of such strains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,005,090 B2
- Document ID: US12005090B2
- Status: Granted
- Kind: B2
- Application number: 17/449,699
- Filed: 2021-10-01
- Published: 2022-08-25
- Granted: 2024-06-11
- Earliest claimed: 2021-02-19
- Assignees: Glac Biotech Co., Ltd.
- Applicants: Glac Biotech Co., Ltd.
- Inventors: Hsieh-Hsun Ho; Ching-Wei Chen; Yu-Fen Huang; Yi-Wei Kuo; Wen-Yang Lin; Yen-Yu Huang
- Web page: https://patentgrep.com/patent/US12005090B2

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 35/745: Bifidobacteria
- A61P 3/04: Anorexiants; Antiobesity agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein is a probiotic composition including Lactobacillus salivarius subsp. salicinius AP-32 that is deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2011127, and Bifidobacterium longum subsp. longum OLP-01 that is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 17345. Also disclosed herein are use of at least one of the abovementioned lactic acid bacterial strains for treating obesity and/or an obesity-related disorder, and for inhibiting fat absorption.

## Claims

### Claim 1

A method for treating obesity and/or an obesity-related disorder in a subject, the method comprising:
administering to the subject in need thereof a pharmaceutical composition consisting of Lactobacillus salivarius subsp. salicinius AP-32 which is deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2011127, and Bifidobacterium longum subsp. longum OLP-01 which is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 17345,
wherein a ratio of a number of Lactobacillus salivarius subsp. salicinius AP-32 to that of Bifidobacterium longum subsp. longum OLP-01 ranges from 1:0.5 to 1:2.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the obesity-related disorder is selected from the group consisting of hypertension, atherosclerosis, a cardiovascular disease, a fatty liver disease, and combinations thereof.

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein the pharmaceutical composition is in a dosage form for oral administration.

### Claim 4 (depends on 1)

The method as claimed in claim 1, wherein the pharmaceutical composition is in a dosage form for topical administration.

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein the ratio of the number of Lactobacillus salivarius subsp. salicinius AP-32 to that of Bifidobacterium longum subsp. longum OLP-01 is 1:1.

### Claim 6

A method for inhibiting fat absorption in a subject, the method comprising:
administering to the subject in need thereof a probiotic consisting of Lactobacillus salivarius subsp. salicinius AP-32 which is deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2011127, and Bifidobacterium longum subsp. longum OLP-01 which is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 17345,
wherein a ratio of a number of Lactobacillus salivarius subsp. salicinius AP-32 to that of Bifidobacterium longum subsp. longum OLP-01 ranges from 1:0.5 to 1:2.

### Claim 7 (depends on 6)

The method as claimed in claim 6, wherein the probiotic composition is a pharmaceutical composition in a dosage form for oral administration.

### Claim 8 (depends on 6)

The method as claimed in claim 6, wherein the probiotic composition is a pharmaceutical composition in a dosage form for topical administration.

### Claim 9 (depends on 6)

The method as claimed in claim 6, wherein the probiotic composition is a food product.

### Claim 10 (depends on 6)

The method as claimed in claim 6, wherein the ratio of the number of Lactobacillus salivarius subsp. salicinius AP-32 to that of Bifidobacterium longum subsp. longum OLP-01 is 1:1.